Incyte, CMS enter license agreement to develop, commercialize povorcitinib in Asia
Click Here to Manage Email Alerts
Key takeaways:
- Povorcitinib is a selective oral Janus kinase 1 inhibitor.
- China Medical System Holding Limited now has the rights to develop and commercialize povorcitinib in parts of Asia.
Incyte has entered into a collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib, the companies announced in a press release.
Povorcitinib is a selective oral Janus kinase 1 inhibitor that treats autoimmune and inflammatory dermatologic disease including nonsegmental vitiligo, hidradenitis suppurativa, prurigo nodularis, asthma and chronic spontaneous urticaria.
This new agreement gives China Medical System Holding Limited (CMS) the rights to develop and commercialize povorcitinib in these indications in mainland China, Hong Kong, Macau, Taiwan and certain countries in Southeast Asia.
“There remains a significant need for new, innovative treatment for vitiligo and other immune-mediated dermatologic conditions, and we look forward to working together with the CMS team to bringing these products to market in China,” Hervé Hoppenot, CEO of Incyte, said in the release.
Incyte will receive an upfront payment from CMS and will be eligible to receive royalties on net sales of the licensed product in CMS’ territory.
Click Here to Manage Email Alerts